Skip to main content
SpringerLink
Log in

Decitabine in myelodysplastic syndromes: profile report

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. McKeage K, Croom KF. Decitabine in myelodysplastic syndromes. Drugs 2006; 66(7): 951–8

    Article  PubMed  CAS  Google Scholar 

  2. Garcia-Manero G. Decitabine in myelodysplastic syndromes: a viewpoint. Drugs 2006; 66(7): 959

    Article  PubMed  Google Scholar 

  3. Saba H. Decitabine in myelodysplastic syndromes: a viewpoint. Drugs 2006; 66(7): 959–60

    Article  PubMed  Google Scholar 

  4. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2Suppl. 1: S4–11

    Article  PubMed  CAS  Google Scholar 

  5. Kantarjian H, Issa J-PJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006 Apr 15; 106(8): 1794–803

    Article  PubMed  CAS  Google Scholar 

  6. Saba HI, Lübbert M, Wijermans PW. Response rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS) [abstract no. 2515]. Blood 2005; 106(11): 706. Plus poster presented at the American Society of Hematology Annual Meeting; 2005 Dec 10–13; Atlanta (GA)

    Google Scholar 

  7. Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2′-de-oxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000 Mar; 18: 956–62

    PubMed  CAS  Google Scholar 

  8. Silverman LR, Demakos EP, Peterson BL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–40

    Article  PubMed  CAS  Google Scholar 

  9. Issa J-PJ, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004 Mar 1; 103(5): 1635–40

    Article  PubMed  CAS  Google Scholar 

  10. Kantarjian H, O’Brien S, Giles F, et al. Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS): comparison of 3 different dose schedules [abstract no. 2522]. Blood 2005 Nov; 106(11): 708

    Google Scholar 

  11. Saba H, Rosenfeld C, Issa JP, et al. First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS) [abstract no. 67]. Blood 2004 Nov 16; 104 (11 Pt 1): 23

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Decitabine in myelodysplastic syndromes: profile report. Drugs Ther. Perspect 22, 6–7 (2006). https://doi.org/10.2165/00042310-200622110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622110-00002

Search

Navigation